

Market Announcement

7 July 2022

Firebrick Pharma Limited (ASX:FRE) – Trading Halt

Description

The securities of Firebrick Pharma Limited ('FRE') will be placed in trading halt at the request of FRE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 11 July 2022 or when the announcement is released to the market.

Issued by

Nikki Ciavatta

Adviser, Listings Compliance (Perth)

7 July 2022

Barbara Lim
Adviser, Listings Compliance
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000

Via Email: tradinghaltsperth@asx.com.au

Dear Barbara

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Firebrick Pharma Limited (ASX:FRE) (**Company**) hereby requests that its securities be placed into an immediate trading halt pending an announcement about the outcome of the appeal filed against the TGA's initial decision not to approve Nasodine® Nasal Spray ("Nasodine") for sale in Australia, based on the existing clinical data (see ASX announcement of 1 March 2022).

The Company requests that trading in its securities be halted until after the expected announcement is made regarding the above or until the market opens on Monday, 11 July 2022, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely



Stephen Buckley
COMPANY SECRETARY